Piper Sandler lowered the firm’s price target on Teladoc to $25 from $30 and keeps an Overweight rating on the shares. The firm is defending Teladoc which will be down considerably following a mixed Q4 print and sobering 2024 guide. Piper pares back long-term growth assumptions.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See today’s best-performing stocks on TipRanks >>
Read More on TDOC:
- Teladoc Inc. Earnings Update: Did it Beat Estimate Forecasts?
- Teladoc (NYSE:TDOC) Delivers Mixed Q4, Stock Drops On Downbeat Outlook
- Teladoc Health Reports Fourth Quarter and Full Year 2023 Results
- Options Volatility and Implied Earnings Moves Today, February 20, 2024
- Teladoc Health Provides Updated Start Time for Fourth Quarter 2023 Earnings Call on February 20, 2024
